Title | G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, Deonarine LDayal, Cyrta J, Davicioni E, Sboner A, Robinson BD, Chinnaiyan AM, Rubin MA, Barbieri CE, Zhou P |
Journal | Nat Commun |
Volume | 12 |
Issue | 1 |
Pagination | 6662 |
Date Published | 2021 Nov 18 |
ISSN | 2041-1723 |
Keywords | Androgen Receptor Antagonists, Animals, Carcinogenesis, Cell Line, Tumor, Cell Movement, Cell Survival, Cullin Proteins, DNA Helicases, Gene Expression Regulation, Neoplastic, Humans, Male, Mice, Mutation, Nuclear Proteins, Poly-ADP-Ribose Binding Proteins, Prostatic Neoplasms, Receptors, Androgen, Repressor Proteins, RNA Helicases, RNA Recognition Motif Proteins, Signal Transduction, Ubiquitin-Protein Ligases |
Abstract | SPOP, an E3 ubiquitin ligase, acts as a prostate-specific tumor suppressor with several key substrates mediating oncogenic function. However, the mechanisms underlying SPOP regulation are largely unknown. Here, we have identified G3BP1 as an interactor of SPOP and functions as a competitive inhibitor of Cul3, suggesting a distinctive mode of Cul3 inactivation in prostate cancer (PCa). Transcriptomic analysis and functional studies reveal a G3BP1-SPOP ubiquitin signaling axis that promotes PCa progression through activating AR signaling. Moreover, AR directly upregulates G3BP1 transcription to further amplify G3BP1-SPOP signaling in a feed-forward manner. Our study supports a fundamental role of G3BP1 in disabling the tumor suppressive Cul3, thus defining a PCa cohort independent of SPOP mutation. Therefore, there are significantly more PCa that are defective for SPOP ubiquitin ligase than previously appreciated, and these G3BP1 PCa are more susceptible to AR-targeted therapy. |
DOI | 10.1038/s41467-021-27024-x |
Alternate Journal | Nat Commun |
PubMed ID | 34795264 |
PubMed Central ID | PMC8602290 |
Grant List | P50 CA211024 / CA / NCI NIH HHS / United States R01 CA221152 / CA / NCI NIH HHS / United States R01 CA125612 / CA / NCI NIH HHS / United States R37 CA215040 / CA / NCI NIH HHS / United States R01 CA213992 / CA / NCI NIH HHS / United States |